{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:06:01Z","timestamp":1790154361336,"version":"4.0.1"},"reference-count":91,"publisher":"European Respiratory Society (ERS)","issue":"181","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2026,6,7]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>With major therapeutic advances driven by cystic fibrosis transmembrane conductance regulator (CFTR) modulators (CFTRm), increasing numbers of women with cystic fibrosis (CF) are living into adulthood and pursuing pregnancy. Women with CF may face pregnancy-related challenges that influence maternal and fetal outcomes. However, long-term data regarding the safety and effectiveness of CFTRm use during pregnancy remain limited.<\/jats:p>\n                  <jats:p>This scoping review aimed to evaluate the existing literature on the effects of CFTRm use in women with CF during pregnancy and the postpartum period, as well as the potential impact on the developing fetus. We analysed clinical studies, registry data and related literature published between 2003 and 2025 to assess reported differences in lung function, birth weight, pregnancy and neonatal complications, mode of delivery and screening biomarkers among pregnancies in women with CF treated with ivacaftor, lumacaftor\/ivacaftor, tezacaftor\/ivacaftor or elexacaftor\/tezacaftor\/ivacaftor, compared with pregnancies not exposed to CFTRm.<\/jats:p>\n                  <jats:p>Available evidence suggests that elexacaftor\/tezacaftor\/ivacaftor may improve maternal health through better lung function and nutritional status, while inadvertent fetal drug exposure has not been clearly associated with serious adverse outcomes. Reported fetal and neonatal outcomes following maternal CFTRm therapy have generally been reassuring. However, long-term effects in exposed children remain uncertain. There is also insufficient evidence to establish the safety of infant exposure or prolonged maternal CFTRm use during lactation. This review highlights the need for future studies evaluating dose optimisation, long-term follow-up of infants and children, and integration of registry data to better define the safety and effectiveness of CFTRm use during pregnancy.<\/jats:p>","DOI":"10.1183\/16000617.0273-2025","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:30:15Z","timestamp":1790152215000},"page":"250273","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Maternal and fetal outcomes associated with CFTR modulator use during pregnancy: a scoping review"],"prefix":"10.1183","volume":"35","author":[{"given":"Zihanjiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasa","family":"Ruseckaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Dobric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-6126","authenticated-orcid":false,"given":"Peter","family":"Wark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imogen","family":"Felton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3004-279X","authenticated-orcid":false,"given":"Jamie","family":"Duckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3361-4941","authenticated-orcid":false,"given":"Peter G.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-9722","authenticated-orcid":false,"given":"Jennifer L.","family":"Taylor-Cousar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Rolnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Menkhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6044-4824","authenticated-orcid":false,"given":"Elena K.","family":"Schneider-Futschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026092301300519000_35.181.250273.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01609-4"},{"key":"2026092301300519000_35.181.250273.2","unstructured":"Cystic Fibrosis Foundation . Understanding Changes in Life Expectancy. www.cff.org\/managing-cf\/understanding-changes-life-expectancy. Date last accessed: 11 May 2025."},{"key":"2026092301300519000_35.181.250273.3","unstructured":"Cystic Fibrosis Trust . UK Cystic Fibrosis Registry 2023 Annual Data Report. London, Cystic Fibrosis Trust, 2024. Available from: www.cysticfibrosis.org.uk\/sites\/default\/files\/2024-11\/CFT_2023_Annual_Data_Report_Oct2024%201.pdf"},{"key":"2026092301300519000_35.181.250273.4","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jcf.2025.07.015","article-title":"PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report","volume":"24","author":"Szentpetery","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jcf.2025.03.009","article-title":"First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: report from the MODUL-CF study","volume":"24","author":"Bonnel","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2026092301300519000_35.181.250273.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2026092301300519000_35.181.250273.10","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026092301300519000_35.181.250273.11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1021\/acsptsci.2c00233","article-title":"In utero mapping and development role of CFTR in lung and gastrointestinal tract of cystic fibrosis patients","volume":"6","author":"Li","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2026092301300519000_35.181.250273.12","doi-asserted-by":"crossref","first-page":"909925","DOI":"10.3389\/fped.2022.909925","article-title":"Congenital etiologies of exocrine pancreatic insufficiency","volume":"10","author":"Scheers","year":"2022","journal-title":"Front Pediatr"},{"key":"2026092301300519000_35.181.250273.13","doi-asserted-by":"crossref","first-page":"914790","DOI":"10.3389\/fped.2022.914790","article-title":"The exocrine pancreas in cystic fibrosis in the era of CFTR modulation: a mini review","volume":"10","author":"McKay","year":"2022","journal-title":"Front Pediatr"},{"key":"2026092301300519000_35.181.250273.14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.14309\/ajg.0000000000003571","article-title":"A comprehensive review of gastrointestinal manifestations in cystic fibrosis in the era of highly effective modulator therapy","volume":"121","author":"Saikumar","year":"2026","journal-title":"Am J Gastroenterol"},{"key":"2026092301300519000_35.181.250273.15","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.3390\/ijms25126692","article-title":"Ocular changes in cystic fibrosis: a review","volume":"25","author":"Liberski","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026092301300519000_35.181.250273.16","doi-asserted-by":"crossref","first-page":"775123","DOI":"10.3389\/fgene.2022.775123","article-title":"Congenital bilateral absence of the vas deferens","volume":"13","author":"Cai","year":"2022","journal-title":"Front Genet"},{"key":"2026092301300519000_35.181.250273.17","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2016.03.041","article-title":"Features of severe liver disease with portal hypertension in patients with cystic fibrosis","volume":"14","author":"Stonebraker","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092301300519000_35.181.250273.18","doi-asserted-by":"crossref","first-page":"116155","DOI":"10.1016\/j.biopha.2024.116155","article-title":"Fetal drug exposure after maternally administered CFTR modulators elexacaftor\/tezacaftor\/ivacaftor in a rat model","volume":"171","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"2026092301300519000_35.181.250273.19","unstructured":"Vertex Pharmaceuticals . TRIKAFTA: Highlights of Prescribing Information. 2025. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/212273s015lbl.pdf"},{"key":"2026092301300519000_35.181.250273.20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jcf.2024.11.014","article-title":"Lens-related ocular changes in fetal rats following in utero exposure to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Zhu","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.21","doi-asserted-by":"crossref","first-page":"e157229","DOI":"10.1172\/jci.insight.157229","article-title":"In utero and postnatal ivacaftor\/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets","volume":"9","author":"Evans","year":"2024","journal-title":"JCI Insight"},{"key":"2026092301300519000_35.181.250273.22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7531"},{"key":"2026092301300519000_35.181.250273.23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcf.2024.09.007","article-title":"CF ferrets exposed to in utero ivacaftor do not develop lens abnormalities","volume":"24","author":"Taylor-Cousar","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001289"},{"key":"2026092301300519000_35.181.250273.25","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jcf.2024.11.011","article-title":"Outcomes of prenatal use of elexacaftor\/tezacaftor\/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis","volume":"24","author":"Metcalf","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal cystic fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of cystic fibrosis","volume":"50","author":"G\u00f3mez-Montes","year":"2023","journal-title":"Fetal Diagn Ther"},{"key":"2026092301300519000_35.181.250273.27","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"2026092301300519000_35.181.250273.28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejogrb.2024.06.045","article-title":"Obstetric and neonatal outcomes among pregnant patients with cystic fibrosis","volume":"300","author":"Amar","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026092301300519000_35.181.250273.29","doi-asserted-by":"crossref","first-page":"107654","DOI":"10.1016\/j.rmed.2024.107654","article-title":"Maternal and fetal outcomes in multiparous women with cystic fibrosis","volume":"228","author":"Cohen-Cymberknoh","year":"2024","journal-title":"Respir Med"},{"key":"2026092301300519000_35.181.250273.30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1753495X221146342","article-title":"Pregnancy in women with cystic fibrosis and diabetes: an audit of outcomes at two tertiary obstetric hospitals in Australia in the pre-cystic fibrosis transmembrane conductance regulator modulator era","volume":"16","author":"Davidson","year":"2023","journal-title":"Obstet Med"},{"key":"2026092301300519000_35.181.250273.31","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004959"},{"key":"2026092301300519000_35.181.250273.32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jcf.2020.09.002","article-title":"Baseline cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression","volume":"20","author":"Cohen-Cymberknoh","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.33","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/aogs.14190","article-title":"Perinatal outcomes in women with cystic fibrosis: data from the Italian Cystic Fibrosis Registry","volume":"100","author":"Padoan","year":"2021","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2026092301300519000_35.181.250273.34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jcf.2019.06.003","article-title":"Pregnancy outcome in women with cystic fibrosis and poor pulmonary function","volume":"19","author":"Reynaud","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.35","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/1471-0528.16423","article-title":"The outcome of pregnancy in women with cystic fibrosis: a UK population-based descriptive study","volume":"127","author":"Ashcroft","year":"2020","journal-title":"BJOG"},{"key":"2026092301300519000_35.181.250273.36","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-211706"},{"key":"2026092301300519000_35.181.250273.37","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2016.1161747"},{"key":"2026092301300519000_35.181.250273.38","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/aogs.13185","article-title":"Pregnancy outcome in women with cystic fibrosis-related diabetes","volume":"96","author":"Reynaud","year":"2017","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2026092301300519000_35.181.250273.39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.rmed.2016.02.010","article-title":"Maternal and perinatal outcomes of pregnancies in women with cystic fibrosis\u2014a single centre case\u2013control study","volume":"113","author":"Girault","year":"2016","journal-title":"Respir Med"},{"key":"2026092301300519000_35.181.250273.40","doi-asserted-by":"crossref","first-page":"98.e1","DOI":"10.1016\/j.ajog.2014.07.018","article-title":"Medical and obstetric complications among pregnant women with cystic fibrosis","volume":"212","author":"Patel","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"2026092301300519000_35.181.250273.41","doi-asserted-by":"publisher","DOI":"10.1177\/1753495X15575628"},{"key":"2026092301300519000_35.181.250273.42","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.12040"},{"key":"2026092301300519000_35.181.250273.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2012.06.013"},{"key":"2026092301300519000_35.181.250273.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828X.2010.01287.x"},{"key":"2026092301300519000_35.181.250273.45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.chest.2024.09.019","article-title":"Impact of cystic fibrosis transmembrane conductance regulator modulators on maternal outcomes during and after pregnancy","volume":"167","author":"Jain","year":"2025","journal-title":"Chest"},{"key":"2026092301300519000_35.181.250273.46","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jcf.2025.01.007","article-title":"Contraceptive use and pregnancy in cystic fibrosis: survey findings from 10 cystic fibrosis centers","volume":"24","author":"Godfrey","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jcf.2025.03.002","article-title":"CFTR modulators and pregnancy outcomes: early findings from a nationwide cohort study","volume":"24","author":"Chouchana","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/1753495X251319588","article-title":"Pregnancy outcomes in patients from a Scottish Adult Cystic Fibrosis Unit taking elexacaftor\/tezacaftor\/ivacaftor, 2020\u2013present","volume":"19","author":"Valcheva","year":"2025","journal-title":"Obstet Med"},{"key":"2026092301300519000_35.181.250273.49","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jcf.2025.06.001","article-title":"Pregnancy and neonatal outcome following in utero exposure to CFTR modulators: a multicentre prospective case series","volume":"24","author":"Gautier","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.50","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.51","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: a two center case series","volume":"20","author":"O'Connor","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.52","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators \u2013 an international survey","volume":"19","author":"Nash","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.53","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jcf.2022.02.006","article-title":"Parenthood impacts short-term health outcomes in people with cystic fibrosis","volume":"21","author":"Kazmerski","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.54","doi-asserted-by":"crossref","first-page":"107868","DOI":"10.1016\/j.rmed.2024.107868","article-title":"Therapeutic drug monitoring of elexacaftor, tezacaftor, and ivacaftor before, during, and after pregnancy in women with cystic fibrosis: an observational study","volume":"236","author":"Shad","year":"2025","journal-title":"Respir Med"},{"key":"2026092301300519000_35.181.250273.55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00404-023-06962-5","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor combination in pregnancy","volume":"309","author":"Cimino","year":"2024","journal-title":"Arch Gynecol Obstet"},{"key":"2026092301300519000_35.181.250273.56","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jcf.2024.06.003","article-title":"Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies","volume":"23","author":"Kowalik","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.18332\/pne\/157586","article-title":"Pregnancy in cystic fibrosis in the era of CFTR modulators: a case series","volume":"36","author":"Sionidou","year":"2023","journal-title":"Pneumon"},{"key":"2026092301300519000_35.181.250273.58","first-page":"100953","article-title":"Comparison of two pregnancies with and without elexacaftor-tezacaftor-ivacaftor in a woman with cystic fibrosis","volume":"83","author":"Chamagne","year":"2023","journal-title":"Respir Med Res"},{"key":"2026092301300519000_35.181.250273.59","doi-asserted-by":"crossref","first-page":"1274303","DOI":"10.3389\/fmed.2023.1274303","article-title":"Maternal, newborn and breast milk concentrations of elexacaftor\/tezacaftor\/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy","volume":"10","author":"Ripani","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026092301300519000_35.181.250273.60","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.61","first-page":"101778","article-title":"Experience to date with CFTR modulators during pregnancy and breastfeeding in the British Columbia Cystic Fibrosis clinic","volume":"40","author":"Goodwin","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"2026092301300519000_35.181.250273.62","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking elexacaftor, tezacaftor, and ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.63","first-page":"101776","article-title":"Successful pregnancy in a cystic fibrosis patient with a severe impairment of lung function receiving elexacaftor-tezacaftor-ivacaftor","volume":"40","author":"Balmpouzis","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"2026092301300519000_35.181.250273.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.01.007"},{"key":"2026092301300519000_35.181.250273.65","first-page":"e17427","article-title":"Cystic fibrosis transmembrane conductance regulator modulators during pregnancy: a case series","volume":"13","author":"Kendle","year":"2021","journal-title":"Cureus"},{"key":"2026092301300519000_35.181.250273.66","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jcf.2019.12.004","article-title":"To be or not to be on CFTR modulators during pregnancy: risks to be considered","volume":"19","author":"Vekaria","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jogn.2016.08.011","article-title":"A case report of pregnancy during use of targeted therapeutics for cystic fibrosis","volume":"46","author":"Ladores","year":"2017","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"key":"2026092301300519000_35.181.250273.68","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcf.2015.11.013","article-title":"A successful uncomplicated CF pregnancy while remaining on ivacaftor","volume":"15","author":"Kaminski","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.69","first-page":"25","article-title":"Potential impact on fertility of new systemic therapies for cystic fibrosis","volume":"16","author":"Jones","year":"2015","journal-title":"Paediatr Respir Rev"},{"key":"2026092301300519000_35.181.250273.70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2374373519826556","article-title":"Two unanticipated pregnancies while on cystic fibrosis gene-specific drug therapy","volume":"7","author":"Ladores","year":"2020","journal-title":"J Patient Exp"},{"key":"2026092301300519000_35.181.250273.71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/a-0973-8565","article-title":"Successful pregnancy of a patient with cystic fibrosis genotype F508del\/F508del and progressed pulmonary destruction on lumacaftor\/ivacaftor","volume":"231","author":"Mainz","year":"2019","journal-title":"Klin Padiatr"},{"key":"2026092301300519000_35.181.250273.72","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2018.05.009","article-title":"Measured fetal and neonatal exposure to lumacaftor and ivacaftor during pregnancy and while breastfeeding","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.73","doi-asserted-by":"crossref","first-page":"e71168","DOI":"10.1002\/ppul.71168","article-title":"Prenatal elexacaftor\/tezacaftor\/ivacaftor treatment prevents meconium ileus, but not exocrine pancreatic insufficiency and lung disease in infants with cystic fibrosis","volume":"60","author":"Aleksander","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"2026092301300519000_35.181.250273.74","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2025.03.006","article-title":"CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: insights from an unsuccessful case","volume":"24","author":"Destoop","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.75","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.7326\/L23-0112","article-title":"Treatment of fetal cystic fibrosis with cystic fibrosis transmembrane conductance regulator modulation therapy","volume":"176","author":"Blumenfeld","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026092301300519000_35.181.250273.76","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/ppul.26809","article-title":"Cystic fibrosis transmembrane conductance regulator modulator administration to a F508del heterozygous infant with meconium pseudocyst and short bowel syndrome: a case report","volume":"59","author":"Stoffella","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026092301300519000_35.181.250273.77","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.043539"},{"key":"2026092301300519000_35.181.250273.78","doi-asserted-by":"crossref","first-page":"102840","DOI":"10.1016\/j.eclinm.2024.102840","article-title":"Global, regional, and national burden of preterm birth, 1990\u20132021: a systematic analysis from the Global Burden of Disease study 2021","volume":"76","author":"Liang","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2026092301300519000_35.181.250273.79","doi-asserted-by":"publisher","DOI":"10.1017\/s0950268819001493"},{"key":"2026092301300519000_35.181.250273.80","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.placenta.2024.06.020","article-title":"Placental chronic inflammatory histopathology and fetal growth in a cohort with universal placental examination","volume":"154","author":"Salafia","year":"2024","journal-title":"Placenta"},{"key":"2026092301300519000_35.181.250273.81","unstructured":"Cystic Fibrosis Western Australia . A Positive Challenge! Pregnancy in Cystic Fibrosis 2016. www.cfwa.org.au\/news\/a-positive-challenge-pregnancy-in-cystic-fibrosis\/. Date last accessed: 20 May 2025."},{"key":"2026092301300519000_35.181.250273.82","unstructured":"NCT04828382: A Prospective Study Evaluating Maternal and Fetal Outcomes in the Era of Modulators. 2021. https:\/\/clinicaltrials.gov\/study\/NCT04828382. Date last accessed: 20 June 2025."},{"key":"2026092301300519000_35.181.250273.83","unstructured":"NCT06797206: An Observational Study to Evaluate the Impact of Pregnancy and Parenthood in Females With Cystic Fibrosis and Their Offspring in the CFTR Modulator Era. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06797206. Date last accessed: 20 June 2025."},{"key":"2026092301300519000_35.181.250273.84","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/diagnostics14111179","article-title":"Diagnosis and management of simple and complicated meconium ileus in cystic fibrosis, a systematic review","volume":"14","author":"Donos","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026092301300519000_35.181.250273.85","doi-asserted-by":"crossref","first-page":"101299","DOI":"10.1016\/j.preteyeres.2024.101299","article-title":"The role of CFTR in the eye, and the effect of early highly effective modulator treatment for cystic fibrosis on eye health","volume":"103","author":"Schneider-Futschik","year":"2024","journal-title":"Prog Retin Eye Res"},{"key":"2026092301300519000_35.181.250273.86","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/ijns9010010","article-title":"Immunoreactive trypsinogen in infants born to women with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor","volume":"9","author":"Patel","year":"2023","journal-title":"Int J Neonatal Screen"},{"key":"2026092301300519000_35.181.250273.87","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jcf.2024.05.007","article-title":"Standards for the care of people with cystic fibrosis (CF); planning for a longer life","volume":"23","author":"Gramegna","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.88","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jcf.2023.10.022","article-title":"A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy","volume":"23","author":"Taylor-Cousar","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026092301300519000_35.181.250273.89","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01208-2019"},{"key":"2026092301300519000_35.181.250273.90","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1758851"},{"key":"2026092301300519000_35.181.250273.91","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01662"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0273-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:30:39Z","timestamp":1790152239000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0273-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":91,"journal-issue":{"issue":"181","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1183\/16000617.0273-2025"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0273-2025","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}